tetano
Editor, Senior Moderator
Nat Commun
. 2021 Nov 4;12(1):6379.
doi: 10.1038/s41467-021-26672-3.
Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
Barak Mizrahi[SUP] #[/SUP][SUP] 1 [/SUP], Roni Lotan[SUP] #[/SUP][SUP] 2 [/SUP], Nir Kalkstein[SUP] 1 [/SUP], Asaf Peretz[SUP] 3 4 [/SUP], Galit Perez[SUP] 3 [/SUP], Amir Ben-Tov[SUP] 3 [/SUP], Gabriel Chodick[SUP] 5 6 [/SUP], Sivan Gazit[SUP] 3 6 [/SUP], Tal Patalon[SUP] 3 6 [/SUP]
Affiliations
Abstract
The short-term effectiveness of a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was widely demonstrated. However, long term effectiveness is still unknown. Leveraging the centralized computerized database of Maccabi Healthcare Services (MHS), we assessed the correlation between time-from-vaccine and incidence of breakthrough infection between June 1 and July 27, the date of analysis. After controlling for potential confounders as age and comorbidities, we found a significant 1.51 fold (95% CI, 1.38-1.66) increased risk for infection for early vaccinees compared to those vaccinated later that was similar across all ages groups. The increased risk reached 2.26- fold (95% CI, 1.80-3.01) when comparing those who were vaccinated in January to those vaccinated in April. This preliminary finding of vaccine waning as a factor of time from vaccince should prompt further investigations into long-term protection against different strains.
. 2021 Nov 4;12(1):6379.
doi: 10.1038/s41467-021-26672-3.
Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
Barak Mizrahi[SUP] #[/SUP][SUP] 1 [/SUP], Roni Lotan[SUP] #[/SUP][SUP] 2 [/SUP], Nir Kalkstein[SUP] 1 [/SUP], Asaf Peretz[SUP] 3 4 [/SUP], Galit Perez[SUP] 3 [/SUP], Amir Ben-Tov[SUP] 3 [/SUP], Gabriel Chodick[SUP] 5 6 [/SUP], Sivan Gazit[SUP] 3 6 [/SUP], Tal Patalon[SUP] 3 6 [/SUP]
Affiliations
- PMID: 34737312
- DOI: 10.1038/s41467-021-26672-3
Abstract
The short-term effectiveness of a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was widely demonstrated. However, long term effectiveness is still unknown. Leveraging the centralized computerized database of Maccabi Healthcare Services (MHS), we assessed the correlation between time-from-vaccine and incidence of breakthrough infection between June 1 and July 27, the date of analysis. After controlling for potential confounders as age and comorbidities, we found a significant 1.51 fold (95% CI, 1.38-1.66) increased risk for infection for early vaccinees compared to those vaccinated later that was similar across all ages groups. The increased risk reached 2.26- fold (95% CI, 1.80-3.01) when comparing those who were vaccinated in January to those vaccinated in April. This preliminary finding of vaccine waning as a factor of time from vaccince should prompt further investigations into long-term protection against different strains.